PMID- 21347780
OWN - NLM
STAT- MEDLINE
DCOM- 20111207
LR  - 20220408
IS  - 1534-4681 (Electronic)
IS  - 1068-9265 (Linking)
VI  - 18
IP  - 8
DP  - 2011 Aug
TI  - Mucinous rectal cancer: effectiveness of preoperative chemoradiotherapy and 
      prognosis.
PG  - 2232-9
LID - 10.1245/s10434-011-1612-8 [doi]
AB  - BACKGROUND: This study investigated the effects of preoperative chemoradiotherapy 
      (PCRT) and the prognoses of patients with mucinous rectal cancer compared with 
      those with nonmucinous cancer. METHODS: We retrospectively reviewed the medical 
      records of 368 patients who underwent curative resection after PCRT, between 2000 
      and 2006, for midrectal to lower-rectal adenocarcinoma. Mucinous cancers were 
      present in 23 patients (6.3%) and nonmucinous cancers in 345. In each patient, 
      clinical stage before chemoradiotherapy was compared with pathologic stage to 
      evaluate the extent of downstaging. Survival and multivariate analyses were 
      performed using clinicopathologic variables. The median follow-up period was 42 
      months (range, 4-105 months). RESULTS: There was no difference in clinical stage 
      between the groups. Although 58 patients (16.8%) in the nonmucinous group 
      achieved pathologic complete responses (pCR), no mucinous group patient showed 
      such a response. T-downstaging was more frequently observed in the nonmucinous 
      than in the mucinous group (189 vs 7 [54.9% vs 30.4%], P = .03), but 
      N-downstaging was similar in the 2 groups. The 5-year overall survival rate (OS) 
      was significantly lower in the mucinous than in the nonmucinous group (64.8% vs 
      79.8%, P = .049). Multivariate analysis revealed that mucinous histotype was an 
      independent (negative) prognostic factor for survival (hazard ratio, 2.36; 95% 
      confidence interval, 1.05-5.3; P = .04). CONCLUSIONS: Patients with mucinous 
      rectal cancer experienced a lower rate of T-downstaging after PCRT and had a 
      poorer prognosis than did patients with nonmucinous cancer.
FAU - Shin, Ui Sup
AU  - Shin US
AD  - Department of Surgery, Korea Institute of Radiological & Medical Sciences, Korea 
      Cancer Center Hospital, Seoul, Korea.
FAU - Yu, Chang Sik
AU  - Yu CS
FAU - Kim, Jong Hoon
AU  - Kim JH
FAU - Kim, Tae Won
AU  - Kim TW
FAU - Lim, Seok-Byoung
AU  - Lim SB
FAU - Yoon, Sang Nam
AU  - Yoon SN
FAU - Yoon, Yong Sik
AU  - Yoon YS
FAU - Kim, Chan Wook
AU  - Kim CW
FAU - Kim, Jin Cheon
AU  - Kim JC
LA  - eng
PT  - Journal Article
DEP - 20110223
PL  - United States
TA  - Ann Surg Oncol
JT  - Annals of surgical oncology
JID - 9420840
RN  - 0W860991D6 (Deoxycytidine)
RN  - 6804DJ8Z9U (Capecitabine)
RN  - Q573I9DVLP (Leucovorin)
RN  - U3P01618RT (Fluorouracil)
SB  - IM
MH  - Adenocarcinoma/pathology/*therapy
MH  - Adenocarcinoma, Mucinous/pathology/*therapy
MH  - Adult
MH  - Aged
MH  - Antineoplastic Combined Chemotherapy Protocols/*therapeutic use
MH  - Capecitabine
MH  - *Chemoradiotherapy
MH  - Deoxycytidine/administration & dosage/analogs & derivatives
MH  - Female
MH  - Fluorouracil/administration & dosage/analogs & derivatives
MH  - Follow-Up Studies
MH  - Humans
MH  - Leucovorin/administration & dosage
MH  - Male
MH  - Medical Records
MH  - Middle Aged
MH  - Neoplasm Recurrence, Local/pathology/*therapy
MH  - Neoplasm Staging
MH  - Preoperative Care
MH  - Prospective Studies
MH  - Radiotherapy
MH  - Rectal Neoplasms/pathology/*therapy
MH  - Retrospective Studies
MH  - Survival Rate
MH  - Treatment Outcome
EDAT- 2011/02/25 06:00
MHDA- 2011/12/13 00:00
CRDT- 2011/02/25 06:00
PHST- 2010/06/09 00:00 [received]
PHST- 2011/02/25 06:00 [entrez]
PHST- 2011/02/25 06:00 [pubmed]
PHST- 2011/12/13 00:00 [medline]
AID - 10.1245/s10434-011-1612-8 [doi]
PST - ppublish
SO  - Ann Surg Oncol. 2011 Aug;18(8):2232-9. doi: 10.1245/s10434-011-1612-8. Epub 2011 
      Feb 23.